2022-503036-13-00RecruitingPhase 2
[18F]AlF-PSMA-11 PET in advanced thyroid and head and neck carcinoma
Prostate-specific membrane antigen in thyroid and head and neck carcinoma: On the utility of [18F]AlF-PSMA-11 PET in advanced disease
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
demonstrate uptake of [¹⁸F]AlF-PSMA-11 in lesions on PET.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 25 May 2023
- Start date
- 1 Feb 2024
- Lead sponsor
- Universitair Ziekenhuis Gent
- Diseases
- Head and neck cancer, Thyroid cancer
- EU CT number
- 2022-503036-13-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with known hypersensitivity to the [¹⁸F]AlF-PSMA-11 or used excipients
Other
- potentially pregnant female patients refusing pregnancy testing at screening
- pregnant or breastfeeding female patients
Who the study is looking for
- 18 years of age or older
- willing and mentally and legally capable of providing written informed consent
- have ≥ 1 measurable lesion of interest of ≥ 1.0 cm on medical imaging
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Ziekenhuis Gent | Gent | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.